Electromed, Inc. Announces Record Revenue in Fiscal 2024 Third Quarter

Rhea-AI Summary

Electromed, Inc. achieves record revenue in the third quarter of fiscal year 2024, with a 15% increase to $13.9 million compared to the prior year. Operating income rises by 54%, net income reaches $1.49 million, and cash balance grows to $11.7 million. The company's direct homecare business revenue increases by 12%, showing strong growth and operational efficiency. The gross profit margin remains stable at 75%. Electromed continues to focus on driving adoption of its products, enhancing shareholder value, and sustaining operating leverage for profitability.

Positive

• Record revenue of $13.9 million in Q3 FY 2024, a 15% increase year-over-year.

• Operating income rises by 54% to $1.84 million, with a strong profitability of 13% of revenue.

• Net income reaches $1.49 million, translating to $0.17 per diluted share.

• Cash balance grows to $11.7 million as of March 31, 2024, reflecting a significant increase.

• Direct homecare business revenue increases by 12% to $12.3 million, showcasing strong growth.

• Gross profit margin remains stable at 75% of net revenues, indicating operational efficiency.

Negative

• None.

Insights

Financial Analyst

The reported 15% revenue growth to <$13.9 million> is a strong indicator of Electromed's market expansion and solid sales execution, particularly in the direct homecare business, which saw a 12% year-over-year increase. An annualized homecare revenue per representative exceeding the company's target hints at a productive sales force. However, the gross margin dip from 75% to 74.8%, while seemingly negligible, could reflect margin pressures from costs related to phasing out previous generator models. The balance sheet strength, with no debt and increased cash holdings by <$4.3 million>, positions the company favorably for future investments or unexpected downturns. The 54% surge in operating income to <$1.841 million>, alongside net income's rise to <$1.493 million>, signals strong operational leverage and efficiency gains. Investors should note that SG&A expenses grew by 8.8%, possibly due to investments in personnel to support sales and marketing efforts, which if managed efficiently can be a positive sign for further growth.

Medical Device Market Analyst

Electromed's performance in the airway clearance technology sector, as evidenced by its record revenue, suggests robust demand for its products. The strategic investments the company has made in its sales force and reimbursement processes appear to be paying off. The slight increase in the annualized homecare revenue per weighted average direct sales representative is indicative of effective scaling in the homecare market segment. Investors should recognize the importance of these operational indicators, as they suggest not only current health but also the company's potential to sustain growth through market penetration. The financial health of the company, with a solid cash position and no debt, could allow for continued investment in innovation and market expansion, which is critical in the rapidly evolving medical device landscape. It will be essential, however, to monitor how the increased SG&A expenses will affect the profitability margins in the long-term.

Growth initiatives drive record revenue

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2024 (“Q3 FY 2024”).

Q3 FY 2024 Financial Highlights

• Net revenues increased 15% to a record $13.9 million in Q3 FY 2024, from $12.1 million in the third quarter of the prior fiscal year.
• Gross margins were 75% of net revenues in the third quarters of both the current and prior fiscal years.
• Operating income increased by 54% to $1,841,000 or 13% of revenue, compared with $1,196,000 or 10% of revenue in the third quarter of the prior fiscal year.
• Net income was $1,493,000 for the quarter, or $0.17 per diluted share, compared to $1,075,000, or $0.12 per diluted share in the third quarter of the prior fiscal year.
• Cash as of March 31, 2024, was $11.7 million, an increase of $4.3 million from the June 30, 2023, balance.

“I am excited to announce another record revenue quarter in the third quarter of fiscal year 2024,” said Jim Cunniff, President, and Chief Executive officer. “Our company continues to operate at a high level, further driving the adoption of our best-in-class product, backed by careful commercial expansion and excellent operational efficiency. Our strategy has again generated double-digit revenue growth, with significant operating leverage that is resulting in strong profitability. The team remains focused on serving patients and providers while simultaneously enhancing shareholder value through strong operating results. I look forward to continuing this momentum into our final quarter of fiscal year 2024.”

Q3 FY 2024 Results

All amounts below are for the three months ended March 31, 2024, and compare to the three months ended March 31, 2023 (“Q3 FY 2023”) unless otherwise noted.

Net revenues grew 14.9% to $13.9 million, from $12.1 million in Q3 FY 2023.

Revenue in our direct homecare business increased year-over-year by 12.0% to $12.3 million, from $11.0 million. The increase in revenue was due to an increase in sales representatives and efficiencies recognized within our reimbursement department as a result of recent investments made to streamline the claims process. Field sales force employees totaled 59 at quarter end, 51 of which were direct sales representatives. The annualized homecare revenue per weighted average direct sales representative in Q3 FY 2024 was $969,000, slightly higher than Electromed’s annual target range of $850,000 to $950,000.

Gross profit increased to $10,382,000, or 74.8% of net revenues from $9,056,000 or 75.0% of net revenues in the prior fiscal year. The increase in gross profit in Q3 FY2024 was primarily due to increased net revenues. The decrease in gross margin compared to Q3 FY 2023 was primarily due to costs associated with the wind down of our previous generator models.

Selling, general and administrative (“SG&A”) expenses were $8,374,000 representing an increase of $680,000, or 8.8%, compared to Q3 FY 2023. The increase in SG&A expense was primarily due to increased share-based compensation expense and payroll expense related to the higher average number of sales, sales support, marketing, and reimbursement personnel to process an increased volume of patient referrals.

Operating income for the quarter was $1,841,000, compared to $1,196,000 in Q3 FY 2023. The increase in operating income was driven primarily by increased net revenues.

Net income for the quarter was $1,493,000, or $0.17 per diluted share, compared to $1,075,000, or $0.12 per diluted share in Q3 FY 2023.

As of March 31, 2024, Electromed had $11.7 million in cash, $23.9 million in accounts receivable and no debt, achieving working capital of $35.0 million, and total shareholders’ equity of $42.6 million. The cash balance reflects an increase of $4.3 million for the nine months ended March 31, 2024, compared to a decrease in cash of $1.4 million in the nine months ended March 31, 2023. This increase in cash in the current year was driven by an increase in operating income and management of working capital.

Conference Call and Webcast Information

A conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, May 7, 2024.

Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1665471&tp_key=f09d972070

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13743606. Additionally, an online replay will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “estimate,” “continue,” “expect,” “intend,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Electromed, Inc.   Condensed Balance Sheets
	March 31, 2024			June 30, 2023
	(Unaudited)			(Audited)
Assets
Current Assets
Cash and cash equivalents	$	11,712,000		$	7,372,000
Accounts receivable (net of allowances for credit losses of $45,000)		23,907,000			24,130,000
Contract assets		642,000			487,000
Inventories		4,178,000			4,221,000
Prepaid expenses and other current assets		592,000			1,577,000
Income tax receivable		291,000			-
Total current assets		41,322,000			37,787,000
Property and equipment, net		5,283,000			5,672,000
Finite-life intangible assets, net		648,000			605,000
Other assets		106,000			161,000
Deferred income taxes		1,542,000			1,581,000
Total assets	$	48,901,000		$	45,806,000
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable		792,000			1,372,000
Accrued compensation		2,987,000			3,018,000
Income tax payable		-			336,000
Warranty reserve		1,525,000			1,378,000
Other accrued liabilities		1,022,000			1,949,000
Total current liabilities		6,326,000			8,053,000
Other long-term liabilities		31,000			86,000
Total liabilities		6,357,000			8,139,000
Commitments and Contingencies
Shareholders' Equity
Common stock, $0.01 par value per share, 13,000,000 shares authorized;
8,655,727 and 8,555,238 shares issued and outstanding, as of March 31, 2024, and June 30, 2023, respectively		87,000			86,000
Additional paid-in capital		20,342,000			18,788,000
Retained earnings		22,115,000			18,793,000
Total shareholders' equity		42,544,000			37,667,000
Total liabilities and shareholders' equity	$	48,901,000		$	45,806,000

Electromed, Inc.   Condensed Statements of Operations
	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2024			2023			2024			2023
Net revenues	$	13,871,000		$	12,068,000		$	39,884,000		$	34,455,000
Cost of revenues		3,489,000			3,012,000			9,459,000			8,386,000
Gross profit		10,382,000			9,056,000			30,425,000			26,069,000
Operating expenses
Selling, general and administrative		8,374,000			7,694,000			25,699,000			22,937,000
Research and development		167,000			166,000			480,000			618,000
Total operating expenses		8,541,000			7,860,000			26,179,000			23,555,000
Operating income		1,841,000			1,196,000			4,246,000			2,514,000
Interest income, net		120,000			26,000			293,000			37,000
Net income before income taxes		1,961,000			1,222,000			4,539,000			2,551,000
Income tax expense		468,000			147,000			1,217,000			418,000
Net income	$	1,493,000		$	1,075,000		$	3,322,000		$	2,133,000
Income per share:
Basic	$	0.17		$	0.13		$	0.39		$	0.25
Diluted	$	0.17		$	0.12		$	0.38		$	0.25
Weighted-average common shares outstanding:
Basic		8,565,725			8,461,531			8,549,352			8,449,623
Diluted		8,892,821			8,710,106			8,822,938			8,694,407

Electromed, Inc.   Condensed Statements of Cash Flows
	Nine Months Ended March 31,
	2024				2023
	(Unaudited)				(Unaudited)
Cash Flows From Operating Activities
Net income	$	3,322,000			$	2,133,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		594,000				370,000
Amortization of finite-life intangible assets		37,000				52,000
Share-based compensation expense		1,250,000				506,000
Deferred income taxes		39,000				32,000
Changes in operating assets and liabilities:
Accounts receivable		223,000				(1,293,000	)
Contract assets		(155,000	)			(284,000	)
Inventories		78,000				(264,000	)
Prepaid expenses and other current assets		1,234,000				105,000
Income tax payable, net		(627,000	)			(270,000	)
Accounts payable and accrued liabilities		(1,386,000	)			(111,000	)
Accrued compensation		(31,000	)			(660,000	)
Net cash provided by operating activities		4,578,000				316,000
Cash Flows From Investing Activities
Expenditures for property and equipment		(265,000	)			(1,221,000	)
Expenditures for finite-life intangible assets		(84,000	)			(54,000	)
Net cash used in investing activities		(349,000	)			(1,275,000	)
Cash Flows From Financing Activities
Issuance of common stock upon exercise of options		111,000				40,000
Taxes paid on net share settlement of stock option exercises		-				(305,000	)
Repurchase of common stock		-				(153,000	)
Net cash provided by (used in) financing activities		111,000				(418,000	)
Net increase (decrease) in cash		4,340,000				(1,377,000	)
Cash And Cash Equivalents
Beginning of period		7,372,000				8,153,000
End of period	$	11,712,000			$	6,776,000

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507898776/en/

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Electromed, Inc.